WO2005060980A1

WO2005060980A1 - Drug for treating disease and drug for treating diabetes

Info

Publication number: WO2005060980A1
Application number: PCT/JP2004/019799
Authority: WO
Inventors: Masaakira Shonago; Takashi Fujita
Original assignee: Masaakira Shonago; Takashi Fujita
Priority date: 2003-12-24
Filing date: 2004-12-24
Publication date: 2005-07-07
Also published as: JPWO2005060980A1

Abstract

It is intended to effectively utilize active carbon as a drug, particularly in the concomitant administration of active carbon with a remedy for a disease, to thereby provide an excellent drug having an improved effect of treating a disease compared with the case of administering active carbon alone. A drug for treating a disease which comprises active carbon and a remedy for a disease as the active ingredients. A drug for treating diabetes which comprises active carbon and an antidiabetic agent as the active ingredients. As the active carbon, use is preferably made of a porous and spherical carbonaceous material and a porous and spherical carbonaceous adsorbent is still preferable. As the antidiabetic agent, an α-glucosidase inhibitor and insulin are preferable.

Description

Description Pharmaceuticals for the treatment of diseases and pharmaceuticals for the treatment of diabetes

The present invention relates to a medicament for treating a disease comprising activated carbon and another therapeutic agent for a disease, and more particularly to a medicament for treating diabetes having an enhanced antidiabetic effect comprising an activated carbon and an antidiabetic agent as active ingredients, that is, a therapeutic agent for diabetes. Background art

Activated carbon is known as a medicament. For example, it has been disclosed that a porous spherical carbonaceous material adsorbent is effective for chronic renal failure patients and liver disease patients (see Japanese Patent Publication No. 62-11611). In addition, it has been reported that a porous spherical carbonaceous material adsorbent has an improving effect on a type 1 diabetes model using rats (see Patent No. 3333811).

Activated carbon is safe and has no strong side effects. For example, it has been disclosed that no abnormal findings or toxic symptoms were found in the acute and subacute toxicity tests of activated carbon (see Japanese Patent Publication No. 62-11611).

However, the medicinal properties of activated carbon itself as a medicine, especially its anti-diabetic effect, are weak, and it cannot be said that activated carbon is still being effectively used as a medicine.

On the other hand, many drugs known as therapeutic agents for diseases have side effects, and these side effects are a serious problem in drug administration. For example, when an α-glucosidase inhibitor, which is an antidiabetic agent, is taken, side effects such as abdominal bloating, high frequency, flatulence of foul odor, and diarrhea (loose stool) are exhibited.

The present invention has been made in view of the above circumstances, and has as its object to promote the effective use of activated carbon as a medicament, and in particular, to simultaneously administer activated carbon and another therapeutic agent for a disease caused by activated carbon alone. It is an object of the present invention to provide an excellent medicine capable of improving the therapeutic effect or reducing the amount of the therapeutic agent used by the combined effect to reduce side effects. Disclosure of the invention

The present inventors have conducted intensive studies to solve the above-mentioned problems. As a result, activated charcoal and antidiabetic agents were administered to patients with type 2 diabetes (NIDD II) and its reserves, impaired glucose tolerance or borderline diabetes. It has been found that the combined use of the compounds improves the blood glucose lowering promoting action synergistically, and has completed the present invention. Furthermore, they have found that activated carbon can reduce side effects caused by an antidiabetic agent administered in combination with activated carbon, and have completed the present invention.

In addition, activated carbon acts without being absorbed from the digestive tract, so the drug interacts with other drugs in the body. They found that they can be used in combination with any therapeutic agent for the disease without acting, and have completed the present invention.

That is, the present invention is a medicament for treating a disease, comprising activated carbon and a therapeutic agent for a disease as active ingredients. The activated carbon in the medicament for treating the disease is preferably a porous spherical carbonaceous substance, and more preferably a porous spherical carbonaceous substance adsorbent.

Further, the present invention is a medicament for treating diabetes containing activated carbon and an antidiabetic agent as active ingredients. The activated carbon in the diabetes treatment drug is preferably a porous spherical carbonaceous substance, and more preferably a porous spherical carbonaceous substance adsorbent.

The antidiabetic agent is preferably a carbohydrate digestive enzyme inhibitor, insulin, an insulin sensitizer or a therapeutic agent for diabetes complications, and may be an α-darcosidase inhibitor, a “monoamylase inhibitor, and insulin. More preferably, it is an _α -dalcosidase inhibitor and insulin. The medicament for the treatment of diabetes can suppress abdominal bloating, high frequency and flatulence of foul odor and diarrhea (loose stool). It is a drug for treating diabetes.

The medicament for treating diabetes can be a medicament for treating type 2 diabetes.

The “medicine” such as a medicament for treating diabetes in the present invention is a concept including a combination of two or more kinds of medicaments, and is referred to as a “combination” in the present invention.

Therefore, specifically, as an embodiment of the present invention,

(1) A therapeutic combination comprising activated carbon and a therapeutic agent for the disease as active ingredients.

(2) The disease-treating combination according to (1), wherein the activated carbon is a porous spherical carbonaceous substance.

(3) The disease-treating combination according to (1), wherein the activated carbon is a porous spherical carbonaceous substance adsorbent.

(4) A combination for the treatment of diabetes comprising activated carbon and an antidiabetic agent as active ingredients.

(5) The combination for treating diabetes according to the above (4), wherein the activated carbon is a porous spherical carbonaceous material.

(6) The combination for treating diabetes according to the above (4), wherein the activated carbon is a porous spherical carbonaceous substance adsorbent.

(7) The combination for treating diabetes according to any one of the above (4) to (6), wherein the antidiabetic agent is an a-gnorecosidase inhibitor or an α-amylase inhibitor.

(8) The combination for treating diabetes according to any one of (4) to (6), wherein the antidiabetic agent is insulin.

(9) The combination for treating diabetes according to any one of the above (4) to (6), wherein the antidiabetic agent is an agent for treating diabetes complications.

(10) The combination for the treatment of diabetes according to the above (7), which is a combination for the treatment of diabetes in which abdominal bloating, high frequency and bad odor flatus and diarrhea (soft stool) are suppressed.

(11) The combination for treating diabetes according to any one of (4) to (10), wherein the combination for treating diabetes is a combination for treating type 2 diabetes. Can be mentioned.

ADVANTAGE OF THE INVENTION According to this invention, an effective treatment is attained by the combination of an activated carbon and a therapeutic agent for a disease, for example, an effective (synergistic) blood glucose reduction by oral administration of an activated carbon and an antidiabetic agent The effect is obtained, and advantages such as the ability to reduce the dose of the antidiabetic agent are obtained. In particular, it is effectively exerted on type 2 diabetes. In addition, the side effects of anti-diabetic agents co-administered can be reduced. For example, side effects such as abdominal bloating, high frequency and malodorous flatus or diarrhea (loose stool) that occur when taking an α-darcosidase inhibitor are effectively prevented. Can be improved. In addition, in the case of complications caused by the progression of diabetes, uremic toxin (uretoxin), which exacerbates the symptoms, is removed by activated carbon, and the complications can be reduced.

Activated carbon acts without being absorbed from the gastrointestinal tract, so it can be used with any therapeutic agent for the disease without causing drug interaction with other drugs in the body. BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the best mode for carrying out the present invention will be described in detail.

The activated carbon used in the present invention is a known substance, for example, wood (oga waste), coal, petroleum, coconut shell, various pitches of petroleum or coal, cellulose, lignin, polyvinyl alcohol (PVA) It can be produced by a known method using a polymer compound such as polysalt (PVC), phenol resin, dibutylbenzene polymer, rayon, polyacrylonitrile (PAN) as a raw material.

Further, from the viewpoint of the shape of the activated carbon used in the present invention, spherical activated carbon, powdered activated carbon, granular activated carbon, fibrous activated carbon, structural activated carbon (sponge, bead) and the like can be mentioned.

In the present invention, any shape of activated carbon can be used, but from the viewpoint of exhibiting a better effect, it is particularly preferable to use spherical activated carbon. The spherical activated carbon in the present invention is not particularly limited as long as it is substantially spherical. For example, a spherical activated carbon which is a so-called porous spherical carbonaceous material is used. In addition to spherical activated carbon, a porous spherical carbonaceous material adsorbent, which is a processed product prepared by oxidizing and reducing porous spherical carbonaceous material (spherical activated carbon) at a high temperature, is used. However, these spherical activated carbons and porous spherical carbonaceous substance adsorbents are preferably used. In the present invention, it is particularly preferable to use a porous spherical carbonaceous substance adsorbent.

The spherical activated carbon preferably has a particle size range of 0.05 to 2 mm in diameter. On the other hand, if it exceeds 2 mm, not only is it difficult to take the drug, but also the desired pharmacological effect is difficult to quickly manifest. Further, a spherical activated carbon having a pore radius of not more than 80 angstroms and a void volume of 0.2 to 1.0 OmlZg is preferable.

The spherical activated carbon preferably used in the present invention is preferably activated carbon having a diameter of 0.05 to 2 mm. The basic method for producing spherical activated carbon is to carbonize the raw material and then to activate the carbon. In preparing the spherical activated carbon, it is not particularly limited, and may be prepared by a known method. The force that can be produced, for example, can be prepared by the following three methods. First, in the first method, the activated carbon powder raw material is granulated into small-grain spheres using a pinner such as a pitch, and then calcined by heating to 600 to 100 ° C in an inert atmosphere, followed by carbonization. Activate at 850-10000 ° C in a steam atmosphere. In the second method, as described in Japanese Patent Publication No. 51-76, for example, pitches are made into small spheres in a molten state, and then infusibilized with oxygen. Activate carbonization under conditions. In the third method, as described in, for example, Japanese Patent Publication No. 59-10930, pitches are formed into a string-like pitch in a molten state, crushed, and then poured into hot water to form a spheroid. After being made infusible with oxygen, carbonization is activated under the same conditions as in the first method.

As the activation method, a method such as chemical activation, air activation or carbon dioxide gas activation can be used in addition to steam activation.

The porous spherical carbonaceous material adsorbent preferably used in the present invention preferably has a diameter of 0.05 to 2 mm and a pore volume of 80 to 1 Å or less. Activated spherical activated carbon (according to the methanol adsorption method using an adsorption amount measuring device) is oxidized at a high temperature (heat treated at a high temperature in an oxidizing atmosphere) and reduced (not to carbon such as nitrogen, argon or helium atmosphere). Perform high temperature heat treatment in an active atmosphere.) The oxidation heat treatment is preferably performed in an atmosphere having an oxygen content of 0.5 to 25% by volume, more preferably in an atmosphere having an oxygen content of 3 to 10% by volume, preferably at 300 to 700 ° C, and more preferably at 400 to 600 ° C. Performed at a temperature of ° C. The reduction treatment is preferably performed in a nitrogen atmosphere at a temperature of 700 to 1100 ° C, more preferably 800 to 100 ° C.

Acidic and basic groups of the porous spherical carbonaceous substance adsorbent obtained by the oxidation and reduction treatment at high temperature (hereinafter, the porous spherical carbonaceous substance adsorbent is also referred to as “spherical adsorbed carbon”). The total acid group (A) 0.30 to 1.2 Ome q / g, the total basic group (B) 0.20 to 0.7 Ome q / g, and the total acidic group (A) total basic The group (B) is preferably adjusted to a range of 0.40 to 2.5. Here, the total acidic group (A) and the total basic group (B) are physical properties that can be quantified as follows by a conventional method.

(A) All acidic groups (A)

Add 1 g of spherical adsorbed carbon ground to 200 mesh or less to 5 Om 1 of 0.05 NaOH solution specified in 0.05 and shake for 48 hours.Then, the spherical adsorbed carbon is filtered off, and Na is determined by neutralization titration. OH consumption.

(Mouth) All basic groups (B)

Add 1 g of spherical adsorbed carbon ground to 200 mesh or less to 5 Om1 of 0.05 HC1 solution specified in 0.05 and shake it for 24 hours.Then, the spherical adsorbed carbon is filtered off, and HC obtained by neutralization titration 1, consumption.

As an example of the spherical adsorbed carbon in the present invention, a spherical carbonaceous substance adsorbent described in Japanese Patent Publication No. 62-11611 can be mentioned. The following is an example of the preparation of spherical adsorbed carbon.

A pitch under which the anisotropic region is not unevenly distributed under a polarizing microscope (hydrogen atom Z carbon atom ratio = 0.55; pour point = 220 ° C) 300 g and naphthalene 100 g are charged into an autoclave equipped with a stirrer and heated at 180 ° C. The mixture was dissolved and mixed, 1200 g of a 0.5% aqueous solution of PVA (gohsenol) was added, followed by vigorous stirring at 140 for 30 minutes and then cooling to room temperature with stirring to obtain spherical particles. After filtering out most of the water, the obtained spherical particles were put into an extractor, and hexane was passed through to extract and remove naphthalene, followed by drying with ventilation. Next, using a fluidized bed, heated air was circulated at a rate of 25 ° C / h to 300 ° C by flowing heated air, and further kept at 300 ° C for 2 hours for infusibility. Subsequently, the temperature was raised to 900 ° C in steam and maintained at 900 ° C for 2 hours to perform carbonization activation to obtain a porous spherical activated carbon. The diameter of the obtained spherical activated carbon was 0.05 to 1.0 mm, and the void volume with a pore radius of 80 Å or less was 0.755 mlZg (by the methanol adsorption method using an automatic adsorption amount measuring device). .

The spherical activated carbon obtained in this way is treated in a fluidized bed at 600 ° C in an atmosphere with an oxygen concentration of 3% for 3 hours, and then heated to 950 ° C in a nitrogen atmosphere and then at 950 ° C for 30 minutes. Holding to obtain spherical adsorbed carbon. The diameter of this spherical adsorbed carbon is 0.05 to 1 mm, and the void volume with a pore radius of 80 on dastrom or less is 0.751 m 1 / g (by the methanol adsorption method using an automatic adsorption amount measuring device). Total acidic group (A) was 0. SA me qZg Total basic group (B) was 0.525 5 me q / g, and total acidic group (A) / total basic group (B) was 1.03. .

As the activated carbon according to the present invention, commercially available products can be used. For example, Clemezin (fine granules) (manufactured by Kureha Chemical Industry Co., Ltd.), which is a spherical adsorption carbon, is commercially available.

In the present invention, examples of therapeutic agents for diseases that are administered in combination with activated carbon include diabetes, diabetic complications (arteriosclerosis, hypertension, nephropathy, neuropathy, diabetic retinopathy, diabetic cataract) liver disease, kidney Disease, mental illness, neurological disease, hyperlipidemia, hypertension, gout (髙 uricemia), retinopathy, cataract, arteriosclerosis, knee inflammation, 脂質 lipoperoxide, cancer, cachexia, Treatment of Crohn's disease (anti-inflammatory, hemorrhoidal disease), erythropoietin anemia, nephrotic syndrome, obesity, lipoprotein lipase hypotension, hyperplasia of matritus, increased metabolism of vitamin D, osteoporosis, inflammation, gastrointestinal disorders, collagen disease, etc. Agents. '

In the present invention, as will be proved later, the combined use of activated carbon and a therapeutic agent for a disease allows the activated carbon to improve the therapeutic effect of the therapeutic agent for a disease, and to exert a synergistic therapeutic effect of both. be able to. Therefore, it is useful as a medicament for treating a disease containing activated carbon and a therapeutic agent for the disease as active ingredients.

In the present invention, when an anti-diabetic agent is used as the therapeutic agent for a disease, it is possible to improve the therapeutic effect of the anti-diabetic agent as a drug for treating diabetes, that is, a therapeutic agent for diabetes, or to synergistically enhance the therapeutic effect for diabetes. it can.

The antidiabetic agent is not particularly limited as long as it is other than the above-mentioned activated carbon. For example, insulin, mono-dalcosidase inhibitor, _α -amylase inhibitor, insulin resistance Performance improvers (eg pioglitazone, TAK-559, rosiglitazone, CS_011,

MK-1 767, LY-811, netoglitazone, JT-501, AZ-1 422, isaglitazone, BMS-29 985 855, KR P-290, GW-4095 44, FK-614, NNC-6100-29 (DRF-275), etc.), biguanides (for example, methonolemin), sulfonylurea (for example, dalibenclamide) Dariclazide, glimepiride, etc.), insulin secretagogues (eg, nateglinide, etc.), therapeutic agents for diabetes complications (aldose reductase inhibitors (eg, epalrestat, etc.), and angiotensin converting enzyme (ACE) inhibitors (eg, Enalapril, cetapril, captopril, imidabril, cilazapril, delapril, lisinopril, quinapril, arasepril, trandolapril, belindopril, temocapril, benazeprilna, etc.), PKC-j3 inhibition!], Angiote Such as rosinoretan, candesartan (cilexetil), vanoresartan, eprosartan, zolasartan, telmisartan, olmesartan (medoxomil), etc .; Nisoldipine, nitrendipine, nifedipine, nilvadipine, parnidipine, benidipine, manidipine, lercanidipine, azelnidipine, etc.).

Among these antidiabetic agents, it is effective to use a single dalcosidase inhibitor, an α-amylase inhibitor, insulin, an insulin sensitizer, or a therapeutic agent for diabetic complications. Preferably, α-darcosidase is used. It is an inhibitor, insulin, and a drug for treating diabetic complications. By using 0: -dalcosidase inhibitor or insulin as an antidiabetic agent as a therapeutic agent for a disease, the combined use of activated charcoal exerts a remarkable effect on the antidiabetic effect of a single dalcosidase inhibitor or insulin.

In addition, in the present invention, by using an α-dalcosidase inhibitor or an α-amylase inhibitor as an antidiabetic agent, abdominal bloating due to administration of a single dalcosidase inhibitor or α-amylase inhibitor ゃ high frequency and bad odor flatus Alternatively, side effects such as diarrhea (loose stool) can be reduced by co-administration with activated carbon.

a-Dalcosidase inhibitors are known substances, and their use is not particularly limited.For example, acarbose, voglibose, valienamin, epirivalol, mao ゥ, perilla, clove, ospice, oregano, peppermint, mouth Extracts such as zumary and basinole are mentioned.

As the α-dalcosidase inhibitor according to the present invention, commercially available products can be used, and, for example, Basin tablets (manufactured by Takeda Pharmaceutical Co., Ltd.), Darcoby (manufactured by Bayer) and the like are commercially available.

The insulin of the present invention is a known substance, and commercially available products can be used. For example, novolapid injection, hyumalog injection, novolin-1 injection, hyumarin R injection, and the like are commercially available. In addition, there are injections, airway spray insulin preparations, etc., depending on the administration form.

The medicament for treating diabetes, which comprises activated carbon and an antidiabetic agent as active ingredients in the present invention, that is, a drug for treating diabetes (hereinafter, also referred to as a drug for treating diabetes) exerts an effect particularly on patients with type 2 diabetes. Is characteristic. The use as the therapeutic agent for type 2 diabetes, as will be proved later, is based on the use of activated carbon for humans first discovered in the present invention as an anti-type 2 diabetes agent.

The medicament for treating a disease of the present invention is preferably administered orally, and the dose is administered in a quantitative range such that each of the constituents, activated carbon and the therapeutic agent for the disease, becomes the usual amount. That is, the oral dose of activated carbon is usually 0.2 to 20 g per day, and a drug for treating one disease is administered in an appropriate amount depending on the drug. For example, α-glucosidase In the case of inhibitors, it is usually from 0.01 to 1,000 mg per day, preferably from 0.1 to 500 mg per day. The medicament for treating the disease is administered (taken) in one or several divided doses a day, and the dose is appropriately increased or decreased depending on the symptoms. Insulin is administered in an appropriate amount that does not cause hypoglycemia depending on the preparation used, the frequency, and the condition, but the amount used for treating the patient is applied.

In administering the medicament for treating the disease of the present invention, a preparation of the activated carbon and the therapeutic agent for the disease as a single agent can be administered, or they can be administered separately. That is, a drug for treating a disease containing activated carbon as an active ingredient and a drug for treating a disease containing a disease treating agent as an active ingredient can be separately administered. In the present invention, a pharmaceutical form that can be separately administered is preferable from the viewpoint of stabilizing the drug and adsorbing the drug. Therefore, the pharmaceutical forms of the therapeutic drug for diabetes and the therapeutic drug for diabetes, which are separately administered and used, are referred to as a combination for treating a disease and a combination for treating diabetes, respectively.

(7) The combination for treating diabetes according to any one of the above (4) to (6), wherein the antidiabetic agent is a ∞-gnorecosidase inhibitor and a ぴ -amylase inhibitor.

(1 1) wherein the combination for treating diabetes is a combination for treating type 2 diabetes (4) to (10) The combination for treating diabetes according to any one of the above.

Can be mentioned.

The medicament for treating a disease of the present invention, particularly a medicament for treating diabetes, is a powder, a granule, a tablet, a sugar-coated tablet, a capsule, a stick IJ, a sachet and the like, respectively, or a mixture of a disease treating agent such as activated carbon and an antidiabetic agent. It can be given in any form of administration, such as the body, or a suspension.

From the above, as particularly preferred embodiments of the present invention,

(1) A medicament for treating diabetes comprising activated carbon and an antidiabetic agent as active ingredients.

(2) A medicament for treating diabetes, comprising a porous spherical carbonaceous substance adsorbent and an antidiabetic agent as active ingredients. (3) A medicament for treating diabetes, comprising activated carbon and a glucosidase inhibitor as active ingredients.

(4) A medicament for the treatment of diabetes, comprising a porous spherical carbonaceous substance adsorbent and 0; gnorecosidase inhibitor as active ingredients.

(5) A drug for treating diabetes containing activated carbon and insulin as active ingredients.

(6) A medicament for treating diabetes, comprising a porous spherical carbonaceous substance adsorbent and insulin as active ingredients. (7) A medicament for treating diabetes, comprising activated carbon and an agent for treating diabetes complications as active ingredients.

(8) A medicament for treating diabetes, comprising a porous spherical carbonaceous material adsorbent and an agent for treating diabetes complications as active ingredients.

Furthermore,

(9) A medicament for treating type 2 diabetes, comprising activated carbon and an antidiabetic agent as active ingredients.

(10) A medicament for treating type 2 diabetes, comprising a porous spherical carbonaceous substance adsorbent and an antidiabetic agent as active ingredients.

(11) A medicament for treating type 2 diabetes, which comprises activated carbon and an α-darcosidase inhibitor as active ingredients.

(12) A medicament for treating type 2 diabetes, comprising a porous spherical carbonaceous substance adsorbent and an α-dalcosidase inhibitor as active ingredients.

(13) A medicament for treating type 2 diabetes, comprising activated carbon and insulin as active ingredients.

(14) A medicament for treating type 2 diabetes, comprising a porous spherical carbonaceous substance adsorbent and insulin as active ingredients.

(15) A medicament for treating type 2 diabetes, comprising activated carbon and an agent for treating diabetes complications as active ingredients.

(16) A medicament for treating type 2 diabetes, which comprises a porous spherical carbonaceous material adsorbent and an agent for treating diabetes complications as active ingredients.

Furthermore,

(17) A combination for treating diabetes comprising activated carbon and an antidiabetic agent as active ingredients.

(18) A combination for treating diabetes comprising a porous spherical carbonaceous substance adsorbent and an antidiabetic agent as active ingredients.

(19) A combination for the treatment of diabetes, comprising activated carbon and an α-dalcosidase inhibitor as active ingredients.

(20) A combination for treating diabetes mellitus, comprising a porous spherical carbonaceous material adsorbent and an α-dalcosidase inhibitor as active ingredients. (21) A combination for the treatment of diabetes comprising activated carbon and insulin as active ingredients.

(22) A combination for treating diabetes, comprising a porous spherical carbonaceous material adsorbent and insulin as active ingredients.

(23) A combination for treating diabetes, comprising activated carbon and an agent for treating diabetes complications as active ingredients.

(24) A combination for the treatment of diabetes, comprising a porous spherical carbonaceous substance adsorbent and an agent for treating diabetes complications as active ingredients.

Furthermore,

(25) A combination for treating type 2 diabetes, comprising activated carbon and an antidiabetic agent as active ingredients.

(26) A combination for treating type 2 diabetes, comprising a porous spherical carbonaceous substance adsorbent and an antidiabetic agent as active ingredients.

(27) A combination for treating type 2 diabetes, comprising activated carbon and an α-dalcosidase inhibitor as active ingredients.

(28) A combination for treating type 2 diabetes, comprising a porous spherical carbonaceous substance adsorbent and an α-glucosidase inhibitor as active ingredients.

(29) A combination for the treatment of type 2 diabetes containing activated carbon and insulin as active ingredients.

(30) A combination for the treatment of type 2 diabetes, comprising a porous spherical carbonaceous material adsorbent and insulin as active ingredients.

(31) A combination for treating type 2 diabetes, comprising activated carbon and an agent for treating diabetes complications as active ingredients.

(3 2) A combination for the treatment of type 2 diabetes, comprising a porous spherical carbonaceous substance adsorbent and an agent for treating diabetes complications as active ingredients.

And the like.

In addition, from the viewpoint that activated carbon acts without being absorbed from the digestive tract, it does not cause drug interaction with other drugs in the body, and it can be used in combination with any therapeutic agent for diseases. Can be Example

Hereinafter, the present invention will be described specifically with reference to examples. Example 1

The blood glucose level of a male (56 years old) glucose intolerant patient was measured according to the following test method. A meal load test (150 g of cooked rice) was performed on the male, and then 2 g of cremedin fine granules (Kureha Chemical Industry Co., Ltd.) (spherical adsorbed carbon) was orally administered after meals. Blood glucose was measured using Glutest Ace R Set (manufacturer: Arkray Factory Co., Ltd .; sales agency: Sanwa Chemical Laboratory Co., Ltd.), before meal load, 1 hour after meal, 2 hours after meal, 3 hours after meal. Was measured. As a control, the same measurement was performed only in the meal load test without sample administration. Table 1 shows the measurement results (blood glucose level; unit: mg / d 1).

table 1 Table 1. Changes in blood glucose (mg / dl)

As is clear from Table 1, the control showed an increase in blood glucose level, but the administration of Kremezin granules significantly reduced the 2-hour value and improved the hyperglycemic state. Example 2

The same male blood glucose level as in Example 1 was measured according to the following test method. 0.2 mg of α-Darcosidase inhibitor Basin tablets (manufactured by Takeda Pharmaceutical Co., Ltd.) was orally administered to the male before meals, and a meal load test similar to that in Example 1 was performed. Samples 1) to (2) were administered orally.

(1) Kremezin fine granules (Kureha Chemical Industry Co., Ltd.) (spherical adsorbed carbon) 2 g

(2) Kremezin fine granules (Kureha Chemical Industry Co., Ltd.) (spherical adsorbed carbon) 4 g

Blood glucose was measured in the same manner as in Example 1. Table 2 shows the measurement results (blood glucose level; unit: mg / d 1). As a control, Table 2 also shows the results without the administration of Basin tablets and Kremezin fine granules and without the administration of Kremezin granules.

Table 2

Table 2. Changes in blood glucose (mg / dl)

As is evident from Table 2, the combined administration of basin and clemezin showed a dose-dependent decrease in blood glucose. Abdominal bloating and flatus, which were observed with basin administration, were significantly improved with the administration of taremedin fine granules. Example 3

Combination with insulin

Insulin treatment for female (89-year-old) patients with type 2 diabetes were administered insulin 12 units before meals, followed by a meal load test (100 g of cooked rice), followed by kremezin fine granules (吳 4 g was orally administered. Blood glucose was measured using Glutest Ace R Set (manufactured by ARKRAY FACTORY CO., LTD., Sold by Sanwa Chemical Laboratory Co., Ltd.) before eating, 1 hour, 2 hours, and 3 hours. The administration of Kremezin granules significantly reduced the values for 2 hours and 3 hours and improved hyperglycemia. Table 3 shows the measurement results (blood glucose level; unit: mg / d 1).

Table 3. Changes in blood glucose (mg / dl)

As is clear from Table 3, the administration of Kremezin fine granules significantly reduced the values for 2 hours and 3 hours and improved the hyperglycemic state as compared to the control. Example 4

Rheumatism due to stiffness of the fingers and pain in the knee joint 22 A woman (56 years old) with rheumatism who is 2 years old receives 2 g of Kremezin fine granules (Kureha Chemical Industry Co., Ltd.) It was administered orally. The history of treatment with antirheumatic drugs was changed to Rimathil after Ridora + Loxonin. Inflammation was significantly improved by limatil, but stiffness of the fingers and keratinization of the hand epidermis did not. One month after administration of Kremezin, the stiffness of the fingers was reduced, the keratinization of the hand epidermis was improved and daily life was improved, and a clear therapeutic effect was observed.

Claims

The scope of the claims

I. A medicament for treating a disease comprising activated carbon and a therapeutic agent for the disease.

2. The medicament for treating a disease according to claim 1, wherein the activated carbon is a porous spherical carbonaceous substance.

3. The medicament for treating a disease according to claim 1, wherein the activated carbon is a porous spherical carbonaceous substance adsorbent.

4. A medicament for treating diabetes, comprising activated carbon and an antidiabetic agent as active ingredients.

5. The medicament for treating diabetes according to claim 4, wherein the activated carbon is a porous spherical carbonaceous substance.

6. The medicament for treating diabetes according to claim 4, wherein the activated carbon is a porous spherical carbonaceous substance adsorbent.

7. The medicament for treating diabetes according to any one of claims 4 to 6, wherein the antidiabetic agent is a carbohydrate digestive enzyme inhibitor.

8. The medicament for treating diabetes according to any one of claims 4 to 6, wherein the antidiabetic agent is an α-dalcosidase inhibitor.

9. The medicament for treating diabetes according to any one of claims 4 to 6, wherein the antidiabetic agent is insulin.

10. The drug for treating diabetes according to any one of claims 4 to 6, wherein the drug for treating diabetes is a drug for treating diabetes complications.

8. The medicament for treating diabetes according to claim 7, which is a medicament for treating diabetes in which abdominal bloating, high frequency and bad odor flatus and diarrhea (loose stool) are suppressed.

12. The pharmaceutical composition for treating diabetes according to any one of claims 4 to 9, wherein the pharmaceutical composition for treating diabetes is a pharmaceutical composition for treating type 2 diabetes.